Publications by authors named "Nadine Goldammer"
Article Synopsis
- The study aimed to evaluate the effects of bimekizumab on patient-reported outcomes and health-related quality of life (HRQoL) for individuals with active psoriatic arthritis (PsA) over a 16-week period, using data from two phase 3 clinical trials.
- Results showed that patients receiving bimekizumab experienced significant improvements in pain, fatigue, physical function, and HRQoL starting as early as week 4, with continuous benefits observed up to week 16 compared to those on placebo.
- The findings suggest that bimekizumab leads to faster and more substantial enhancements in patient symptoms and overall quality of life in patients who are either new to biologic treatments or those with previous
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
Désirée van der Heijde Lianne S Gensler Atul Deodhar Xenofon Baraliakos Denis Poddubnyy Nadine Goldammer
Ann Rheum Dis
May 2020
Article Synopsis
- Bimekizumab, a treatment that targets IL-17A and IL-17F, was tested in a phase IIb study to evaluate its effectiveness and safety in patients with active ankylosing spondylitis (AS).
- The study involved 303 participants who were randomly assigned to different doses of bimekizumab or a placebo, with the primary measure of success being the ASAS40 response after 12 weeks.
- Results showed that patients receiving bimekizumab had significantly better outcomes compared to placebo, with sustained benefits observed up to 48 weeks, alongside a manageable safety profile.
Objective: In patch-based transdermal drug delivery, adhesiveness is critical for safe and effective treatment, especially in Parkinson's disease (PD) where excessive sweating is common. This study compared the adhesiveness of two transdermal patch formulations of rotigotine (improved room temperature-stable [PR2.3.
View Article and Find Full Text PDFBackground: Restless legs syndrome (RLS) has been associated with insomnia, decreased quality of life, and increased morbidity and mortality in end-stage renal disease. This randomized controlled trial investigated effects of rotigotine in patients with RLS and end-stage renal disease.
Study Design: Double-blind placebo-controlled study.